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Abstract
Mycobacterium tuberculosis (M.tb) is the second leading infectious cause of death worldwide and the primary cause of death
in people living with HIV/AIDS. There are several excellent animal models employed to study tuberculosis (TB), but many
have limitations for reproducing human pathology and none are amenable to the direct study of HIV/M.tb co-infection. The
humanized mouse has been increasingly employed to explore HIV infection and other pathogens where animal models are
limiting. Our goal was to develop a small animal model of M.tb infection using the bone marrow, liver, thymus (BLT)
humanized mouse. NOD-SCID/cc
null mice were engrafted with human fetal liver and thymus tissue, and supplemented with
CD34+ fetal liver cells. Excellent reconstitution, as measured by expression of the human CD45 pan leukocyte marker by
peripheral blood populations, was observed at 12 weeks after engraftment. Human T cells (CD3, CD4, CD8), as well as
natural killer cells and monocyte/macrophages were all observed within the human leukocyte (CD45+) population.
Importantly, human T cells were functionally competent as determined by proliferative capacity and effector molecule (e.g.
IFN-c, granulysin, perforin) expression in response to positive stimuli. Animals infected intranasally with M.tb had
progressive bacterial infection in the lung and dissemination to spleen and liver from 2–8 weeks post infection. Sites of
infection in the lung were characterized by the formation of organized granulomatous lesions, caseous necrosis, bronchial
obstruction, and crystallization of cholesterol deposits. Human T cells were distributed throughout the lung, liver, and
spleen at sites of inflammation and bacterial growth and were organized to the periphery of granulomas. These preliminary
results demonstrate the potential to use the humanized mouse as a model of experimental TB.
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Introduction
Tuberculosis, caused by M.tb, is a major global health threat.
Approximately 2 billion people (one-third of the world’s popula-
tion) are estimated to be latently infected and nearly 9 million
people became newly infected in 2011 [1]. M.tb is the second
leading infectious cause of death worldwide and the leading cause
of death in people with HIV/AIDS [1]. Of great concern is the
growing incidence of multi- and extensively drug resistant isolates
of M.tb associated with case mismanagement and immune
compromise due to HIV infection [1–3]. There is thus an urgent
need to develop and test new vaccines and drug compounds to
prevent and treat TB. Towards this end, development of
additional animal models to complement existing models and
allow new avenues of discovery is needed.
Several excellent animal models are available to study M.tb
infection, including mice, guinea pigs, rabbits, cattle, and non-
human primates (NHP) [4–9]. Mice are the most widely used
model because they are easy to use, inexpensive, and reagents are
readily available. An important limitation of this model, though, is
the lack of granuloma formation similar to human infection [6,9–
11]. The NHP, rabbit, and guinea pigs develop necrotic lesions
similar to human TB disease [12]. Immunological reagents are
limiting for the rabbit, guinea pig, and cow, however; and, like the
mouse, these models are not amenable to the study of HIV/M.tb
co-infection.
A broad spectrum of TB disease states can develop in the NHP,
and co-infection can be simulated using simian immunodeficiency
virus (SIV) and M.tb [5,13,14]. Infection with SIV reproduces
many clinical features of HIV and SIV/M.tb co-infection promotes
aggressive TB disease and reactivation in latency models [13–15].
The significant cost (animals, housing, personnel) as well as
regulatory issues limit the use of the NHP co-infection model on
broader scale. Further, there are significant differences between
SIV and HIV including genetic heterogeneity and receptor usage
for host cell entry [16]. Thus, there is a need for a small animal
model that is: less expensive, available in larger numbers, does not
require specialized facilities and staff, can take advantage of the
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availability of human reagents, and can be infected with HIV as
compared to SIV.
The development of the humanized BLT mice has recently
opened new avenues of study for important human diseases.
Several studies have demonstrated the potential to utilize this
model to study HIV virus [17–20] and a few other pathogens
where host tropism limits use of other animal models [21–23].
Currently, the humanized BLT mouse has not been developed for
M.tb infection and there is no small animal model to study co-
infections, such as HIV/M.tb. Such a model is urgently needed to
improve our understanding of the human immune response to
M.tb, advance our knowledge of HIV/M.tb co-infection pathobi-
ology, inform vaccine development, and guide drug development
to reduce side effects and drug interactions.
Our studies demonstrate that the humanized BLT mouse
develops TB and displays pathology similar to that observed in
infected humans. We show here that humanized mice were
successfully reconstituted with human leukocytes (including T
cells, macrophages, natural killer cells, and antigen presenting
cells). Following M.tb infection, humanized BLT mice displayed
progressive and disseminated bacterial infection, and a spectrum
of organized lesions with necrotic centers at sites of infection along
with cholesterol crystal deposits and bronchial obstruction. We
further demonstrate that human T cells (CD4+ as well as CD8+)
and monocytes/macrophages are distributed normally in tissue.
Importantly, human T cells in our mouse model proliferate in
response to activation, express effector molecules (e.g. IFN-c,
granulysin), and are recruited to and organized at sites of infection.
These preliminary studies support the exciting possibility of using
this small animal model to understand the human immune
response to M.tb and indicate the potential to develop a HIV/M.tb
co-infection model.
Results
Production of the Humanized BLT Mouse Model to Study
TB
There are several different mouse models that are generally
described as ‘‘humanized’’ based on transgenic expression of
human genes, adoptive transfer of human PBLs, human stem cell
transplant, and many more. For a full description and comparison
of these models please see the following reviews [24,25]. Of these
models, the bone marrow, liver, thymus (or BLT) described by J.V.
Garcia and colleagues [26], and reproduced here, is the most
difficult to generate because of the requirement for surgical
engraftment of human fetal tissue in the mouse kidney capsule.
We routinely engraft 35 to 40 mice with human fetal tissues
from an individual donor for various studies by members of our
collaborative group. The average reconstitution level varies from
donor to donor but is in the 30 to 50% range across many groups.
Individuals within each cohort can have relatively large variations
in reconstitution levels with ranges between 5 to 80% not being
unusual; similar findings have been reported by others. Animals
are individually identified so that differences in experimental
outcome can be assessed relative to reconstitution. For many
experimental outcomes, the differences in the levels of reconsti-
tution do not have a major impact. For most experiments, we use
humanized mice produced from different donors to compensate
for individual variations. Of course, numbers of animals needed to
obtain robust data depend on a power analysis and expected
meaningful differences between groups. Depending on the type of
experiment, animals can be blocked by donor and/or ranges in the
level of reconstitution to decrease the sources of variation in the
statistical analysis.
Though technically challenging, this model has been reported to
achieve reconstitution of both helper and cytotoxic (CTL) T
lymphocytes and antigen presenting cells [20,26], the interactions
of which are critical to studies of TB. As shown in Figure 1, 2, and
S1, we could successfully reconstitute human immune populations
using NOD/SCID/cc
null (NSG) mice engrafted with human fetal
liver and thymus tissues and CD34+ cells as previously described
[26]. Twelve weeks post-engraftment, our BLT mice had high
levels of human leukocytes (CD45+ cells) in peripheral blood
(average 27% of the total CD45+ cells, n = 44) (Figure 1A).
Immediately prior to infection, human leukocytes were further
evaluated in the peripheral blood of BLT mice to determine levels
of human T cells, T cell subsets (CD4, CD8), and antigen
presenting cells (APC). Figure 1A and B demonstrate that a large
proportion of the total human leukocytes were T cells (average of
71% of the total human CD45+ population), including both CD4
and CD8 T cells subsets. The circulating human leukocyte pool
included small numbers of CD3-CD56+ Natural Killer (NK) cells
(Figure 1B). Human cells expressing the CD14 marker identifying
monocyte/macrophages were also observed, in agreement with a
previous report [26]. To evaluate the potential for these cells to
activate T cells, we further evaluated expression of key surface
markers by CD14+ cells in this model. As shown in Figure 1D, the
CD14+ population expresses receptors of importance for antigen
presentation (HLA-DR) and lymphocyte activation (CD40, CD80,
and CD86).
Tissue Distribution of Human Leukocytes in Humanized
BLT Mice
TB is primarily a disease of the lung; however, the bacteria can
additionally disseminate to and cause immune-mediated pathology
in many organs. To assess the potential for human leukocytes to
migrate to tissues, we evaluated leukocyte populations in the lung,
spleen, and liver tissues of BLT humanized mice (Figure S1).
Organs were harvested following reconstitution ($12 wk), pro-
cessed to single-cell suspensions, and labeled with human
leukocyte surface phenotype markers (CD45, CD3, CD4, CD8,
CD14, CD56, CD1a), or isotype-matched nonspecific antibody as
a control, and analyzed by flow cytometry. Human leukocytes
(CD45+ cells) were abundant in the spleen (Figure S1) of non-
infected BLT mice and could also be found in the lung and liver. T
cells (CD3+) were especially noted in the spleen and liver, while a
large population of cells with a monocyte/macrophage phenotype
(CD14) was noted in the lung. Cells with a tissue DC phenotype
(CD45+CD142CD1a+) were also observed in the lung, liver, and
spleen (data not shown) similar to reports by Melkus, et al, [26].
Both CD4+ and CD8+ T cell subsets were represented in all 3
tissues, while NK cells (CD56+), though low, were most abundant
in the spleen, similar to previous reports with CD34+-reconstituted
NSG mice (Figure S1). In samples from the blood and spleen, the
CD4+ and CD8+ T cell subsets generally accounted for .95% of
the total CD3+ population. A preliminary experiment with
samples from 1 animal demonstrated that human CD3+ cells
expressing the gamma delta T cell receptor (cd-TCR) can also
develop in our BLT mouse (data not shown) as previously
described for non-BLT humanized mouse models [27]. In both
blood and tissue, the NK cells and APC populations generally
accounted for ,50% of the CD3- (non-T cell) CD45+ cells. This
suggests that other human leukocytes, such as B cells, also
comprise a large part of the non-T cell population as well. Overall,
the distribution of human leukocyte populations that we observed
in our model is fairly consistent with those reported by Melkus,
et al., [26] though we noted generally less human leukocytes in the
liver in our mice (Figure S1).
Experimental Tuberculosis in the Humanized Mouse
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Functional Potential of Splenic T Cell Populations in the
BLT Mouse
Though human T cells are generally well reconstituted in
various humanized mouse models, in other reports these cells
have been shown to have functional defects [28,29]. The BLT
model is the most advanced in this regard, and results from a
small number of studies show the potential for T cells from
these models to recognize antigen, proliferate, and express some
human cytokines and Granzyme B upon activation [20,26,27].
Herein, we assessed the functional potential of T cells from
Figure 1. Production of the humanized BLT mouse to study TB. NOD/SCID/cc
null (NSG) mice were engrafted with human fetal liver and
thymus, and supplemented with CD34+ cells. Shown in A, flow cytometry analysis displaying side scatter (SSC) and forward scatter (FSC)
characteristics (Gate 1) of isolated peripheral blood from a representative BLT mouse twelve weeks post-engraftment. Plots 2–4 are the gating
strategy for selection of cells expressing human CD45 pan leukocyte marker, the corresponding isotype control (IgG1 PE Cy7), and the CD3+
population subgate. B, percentage of the gated cells expressing markers for T cell subsets (CD4, CD8), NK cells (CD32CD56+) and monocyte/
macrophages (CD14+). C, average leukocyte % among gated CD45 cells in four groups of reconstituted BLT mice (n = 44) used for the subsequent
studies (Fig. 2–8). D shows the expression of antigen presenting cells (APC) markers relevant to antigen presentation (HLA-DR) and T cell activation
(CD40, CD80, CD86) expressed by peripheral blood monocyte/macrophages.
doi:10.1371/journal.pone.0063331.g001
Experimental Tuberculosis in the Humanized Mouse
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humanized mice generated in our laboratory and expanded the
characterization of the human CTL repertoire that can be
activated (Figure 2). Using anti-CD3/CD28 or recombinant IL-
15 (rIL-15), we observed a robust proliferative response by both
CD4+ and CD8+ T cells, as measured by intracellular levels of
the Ki67 marker (Figure 2 B, lower plots). This effect was also
very evident from the change in % of total cells in the human
CD45+ cell gate following 5 d of activation with rIL-15
(Figure 2B, upper panels). Importantly, both T cell populations
expressed augmented levels of the effector molecules IFN-c,
perforin, and granulysin in response to activation as shown by
the color dot plot overlays in Figure 2C. Similar to human
peripheral blood T cells [30], CD8+ T cells constitutively
express perforin and granulysin, and can also greatly increase
expression of these cytotoxic/antibacterial molecules upon
activation. We additionally show that splenic T cells from
BLT mice are able to proliferate and increase effector protein
expression in response to recombinant human IL-15 (Figure 2C),
an important molecule for T cell survival and effector activity.
Development of M.tb Infection in the BLT Mouse
Currently, there are no published studies, to our knowledge,
describing M.tb infection in the BLT, or other humanized mouse
models. To evaluate the development of M.tb, we began by
infecting BLT mice i.n. with a 106 CFU of a strain of M.tb that
expresses a red fluorescent protein (tdTomato M.tb H37Rv) as a
proof of concept study. In subsequent experiments, groups of
animals (n = 3–5) were infected with logarithmically decreasing
doses ranging from 106-102 CFU. Using an in-vivo imaging system
(IVIS), we were able to monitor progressive bacterial infection as
described [31] within the lungs of live mice at weekly intervals
(Figure 3A). Compared to the control animals, bacterial infection
could occasionally be observed in the lung of M.tb infected mice
from 1 week onward in groups receiving 105 or 106 CFU (Fig. 3A).
In groups infected with lower doses (102,103 or 104 CFU),
infection was generally not observable via in vivo imaging until 2–3
weeks post-infection (p.i.) (data not shown). In all experiments, the
sensitivity for in vivo imaging declined after 4 weeks, especially at
sites of dissemination, presumably due to loss of the plasmid
expressing the red fluorescent protein. CFU analysis at weekly
Figure 2. Functional potential of splenic T cell populations in the BLT mouse. Spleens were disrupted to single-cell suspensions and
activated with control (media), antibodies to human CD3/CD28, or rIL-15 (15 ng/ml) for 5 days. Following activation, the surface expression of cellular
phenotype markers (CD45, CD3, CD4, and CD8) and intracellular proteins (Ki67, granulysin, perforin, and IFN-c) was detected using flow cytometry.
Shown in A are side scatter and forward scatter characteristics of isolated splenocytes (Gate 1), gating strategy to enable analysis of human CD45+
and CD3+ cell populations and individual T cell (CD4 and CD8) subset gating. B, increase in % of human CD45+ cells within the isolated splenocytes
following 5 d activation with recombinant IL-15 (15 ng/ml) (upper plots) and activation-induced increase in expression of the proliferation marker
Ki67 (lower plots) by treatment displayed as a color dot plot overlay. C, expression of effector molecules (granulysin, perforin, IFN-c) shown by dot
plot overlays demonstrating inducible expression upon activation with CD3/CD28 (red) and rIL-15 (blue) compared to non-activated cells (black).
Data shown in A, B, and C is from a representative mouse (n = 3).
doi:10.1371/journal.pone.0063331.g002
Experimental Tuberculosis in the Humanized Mouse
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time points (Figure 3B) further demonstrates the ability of M.tb to
progress in the lungs and disseminate to various organs within
BLT mice from 2–4 weeks p.i.
Tissue Pathology in M.tb-infected BLT Mice
To evaluate the development of TB in humanized mice, mice
were sacrificed at specified time points, and tissue preserved for
analysis. The left lung lobe and a lobe of liver, along with the
entire spleen, were weighed and used for CFU enumeration. The
remaining lung and liver tissue were used to evaluate tissue
pathology and bacterial load using light microscopy following
hematoxylin and eosin (H&E) and acid fast bacilli (AFB) staining.
Figure 4A shows H&E and AFB images at various time points
from BLT mice infected with a high dose (106 CFU) of tdTomato
H37Rv M.tb. At 2 weeks p.i., multiple foci of mild interstitial
inflammation were observed interspersed with normal areas of
lung. The few observed bacteria were contained within areas of
inflammation. Bacteria were also observed in the bronchus (data
not shown); although inflammatory cell obstruction was not seen at
2 weeks p.i. By week 3 p.i., we observed severe interstitial
inflammation along with thickened alveolar walls and perivascular
inflammation. Bacterial clustering was evident and primarily
contained within these areas of inflammation. Additionally,
bronchial obstruction was also observed (data not shown, but
shown for a different group in Figure 5). At week 4 p.i., granuloma
formation was observed with cellular cuffing and central necrosis.
Bacteria were contained in clusters around the periphery of the
granuloma within alveolar pockets. Bacterial debris was also seen
scattered throughout the necrotic center of the granuloma, along
with pycnotic nuclei and cellular fragmentation (Figure 4A).
Figure 4B shows liver pathology from BLT humanized mice
infected with 106 tdTomato H37Rv M.tb at various times p.i. At
weeks 3 and 4 p.i., multiple areas of organized inflammatory foci
are observed throughout the tissue with bacteria relatively
contained within the regions of inflammatory response. No
significant duct obstruction was noted in the liver, even at 4
weeks p.i.
M.tb Infection in Control NSG Mice without Human
Leukocytes Differs from that Observed in Humanized
Mice
To evaluate the contribution of the innate immune system of the
mouse in our studies, we also infected a small group (n = 4) of non-
humanized NSG mice (Figure S2) and used one non-infected NSG
Figure 3. Progression of M.tb infection in humanized BLT mice. Animals were infected i.n. with CFU tdTomato H37RV M.tb and in-vivo
imaging (IVIS) performed at weekly time points. Shown in A is the fluorescent intensity signal from a group of animals infected with 106 CFU
represented with a pseudocolor scale ranging from yellow (most intense) to dark red (least intense) and IVIS images of BLT mice; across: non-infected
control mouse and M.tb infected BLT mice at 1, 2, and 4 weeks p.i. B, bacterial burden (CFU) are shown per milligram (mg) of tissue from individual
animals (n = 3 per time point) at 2, 3, and 4 weeks p.i.
doi:10.1371/journal.pone.0063331.g003
Experimental Tuberculosis in the Humanized Mouse
PLOS ONE | www.plosone.org 5 May 2013 | Volume 8 | Issue 5 | e63331
mouse as a control. These animals were infected with 105 CFU
tdTomato M.tb H37Rv instead of 106 due to concerns for a greatly
accelerated course of infection due to the lack of an adaptive
immune system. Surprisingly, these animals did not all rapidly
succumb to disease as expected, given the significant immune
deficiencies of these animals. Of the 4 infected animals, 1 expired
at ,1 week and the remaining animals were euthanized at 2
(n = 1), and 6 (n = 2) weeks. The animal that died at ,1 week died
as a consequence of anesthesia complications, and was not thought
to have succumbed to infection. To assess disease, tissues were
harvested at 2 and 6 wk p.i. At week 2 p.i., we observed scattered
areas of inflammation in the lung with slight interstitial and
alveolar wall thickening (Figure S2A, H&E). Bacterial infection
was mostly diffuse with occasional interstitial macrophages
containing relatively few bacilli (Figure S2A, AFB). By week 6
p.i., considerable interstitial thickening due to inflammation was
observed along with intra-alveolar infection (Figure S2A, H&E).
Bacterial clustering was seen and contained to areas of inflamma-
tion, primarily within alveolar sacs (Figure S2A, AFB). At this time
point, bacterial infection was further seen in the bronchial
epithelial wall (data not shown). Within the liver at 2 weeks p.i.,
normal tissue architecture was observed, along with minor
inflammation and relatively few bacilli (Figure S2B). Throughout
the liver at week 6 p.i., primarily neutrophilic areas of
inflammation were seen containing bacteria (Figure S2B). The
extensive granulomatous response observed in the humanized
NSG mice was not observed in these mice lacking reconstitution
with human cells. Subsequent studies with lower doses of M.tb in
the BLT mice (Figure 5) confirmed that these observations were
not due to differences in dose.
TB in Humanized Mice Infected with a Low Dose of M.tb
Though we observed disease pathology consistent with TB
development with high dose infection in our proof of concept
Figure 4. Lung and liver pathology in M.tb-infected humanized mice. M.tb-infected humanized mice have lung and liver pathology
consistent with development of TB. Animals were infected i.n. with 106 CFU tdTomato H37RV M.tb after verification of appropriate reconstitution with
human leukocytes. Shown are images captured by brightfield microscopy following staining of infected tissues using hematoxylin and eosin (H&E)
and acid-fast stain (Ziehl-Neelson) to detect acid-fast bacilli (AFB). The images show tissue damage and inflammation localized to M.tb bacilli in
formalin-fixed tissue sections of BLT mice infected i.n. with 106 cfu tdTomato M.tb H37Rv. Images are representative of mice sacrificed at 2, 3, and
4 wk p.i. described in Fig. 3. Shown in A is the lung tissue pathology visualized by H&E staining (left panels, 4X). Localization and burden of bacilli are
shown in right panels (40X) from the region indicated in the H&E image, as visualized by acid fast and hematoxylin staining. B, liver tissue pathology
at 2, 3, and 4 weeks p.i. (H&E 10X, AFB 40X of indicated region).
doi:10.1371/journal.pone.0063331.g004
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studies, lower dose infections with a longer disease course are more
relevant to human disease. Preliminary studies with i.n. infections
of 102–106 CFU indicated than when lower doses (102 and 103
CFU) were used, poor growth and dissemination was observed
when studies were terminated from 1–4 wk p.i. To further
evaluate the development of disease with lower dose infection
we repeated our studies using i.n. infection with 102 CFU (actual
delivered dose of 250 CFU) and extended the time frame of
observations. Of these animals (n = 6), 2 animals succumbed early
in infection (3 weeks) while the remainder (n = 4) were euthanized
from 6–8 weeks p.i. Figure 5A shows the gross lung anatomy from
a control non-infected BLT mouse (top) and from an M.tb infected
BLT mouse (bottom). The H&E image from the M.tb infected
mouse shows large lung lesions consistent with TB throughout the
lung compared to the lung from the control mouse. At 7 weeks p.i.
(Figure 5B), granuloma formations were observed in the lung of
BLT mice with substantial bacterial clustering peripheral to
pathology (Figure 5B). There was little additional change in lung
pathology from 6 to 8 wk p.i. (data not shown). Of interest,
bronchial obstruction containing large numbers of bacteria and
cholesterol crystal formation was observed within M.tb infected
BLT mouse granulomas in the lung (Figure 5B). In the liver,
diffuse areas of inflammation were further observed along with
bacilli contained within the pathological foci (Figure 5C).
Human T Cells are Recruited to and Organize at Sites of
Inflammation Following M.tb Infection
The lymphocytic mantle, composed primarily of T lympho-
cytes, is a key feature associated with M.tb containment in the
granuloma. Here, immunohistochemistry (IHC) was performed on
formalin-fixed, paraffin-embedded tissue to determine if this
classical feature, associated with both protective host response
and immune-mediated pathology, occurs in our model. Consistent
with human tissue and other animal models, T cells were
characteristically organized to the outer area of sites of infection
and/or inflammation. At 3 weeks p.i., human CD3+ cells (T cells)
were detected in the periphery of lung granulomas and foci of
infection in both lung and liver (Figure 6). Similarly, T-cells were
also found in lesser numbers in the center of larger lung
granulomas (Figure 6A) and adjacent vasculature in the lung
and liver. These results suggest that the human T cells in the BLT
Figure 5. TB in humanized mice infected with a low dose of M.tb. Animals were infected i.n. with 250 CFU tdTomato H37RV M.tb after
verification of appropriate reconstitution with human leukocytes. Shown are images captured by brightfield microscopy following analysis of lung
and liver from a representative animal (n = 11). The images demonstrate tissue damage and inflammation (hematoxylin and eosin, H&E) localized to
M.tb bacilli (acid fast bacilli, AFB) in formalin-fixed tissue sections from lung and liver of BLT mice sacrificed at 6–8 weeks p.i. Shown in A are gross lung
lobes (left panels) and cross sections of whole lung stained with H&E, captured using a stereomicroscope. B, Lung tissue pathology visualized by H&E
staining (left panels) and AFB (right panels). Top panels (20X) demonstrate bronchial obstruction in the lung and the large numbers of bacteria within
the obstruction. Middle panels (20X) show cholesterol crystal deposits (black arrow) observed in large granulomas at later stages ($6 wk) of infection.
Bottom panels (4X) shows center of large, coalescing granulomas characterized by necrosis and lack of AFB. C, shown is liver tissue pathology (left
panel, 10X) and AFB (right panel, 40X) in the indicated region). Images are from lung and liver of a representative animal (n = 6).
doi:10.1371/journal.pone.0063331.g005
Experimental Tuberculosis in the Humanized Mouse
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mouse are able to respond to cytokine/chemokine gradients at
sites of M.tb infection.
Discussion
Understanding the human immune response to M.tb is critical
for the development of countermeasures to prevent, diagnose, and
treat TB. An animal model that would enable the study of human
cell mediated immunity to M.tb and especially, investigations of
HIV/M.tb co-infection would have tremendous value. Our studies
show, for the first time, that the humanized BLT mouse has
promise as small animal model of experimental TB. We have
successfully generated BLT mice with a high level of human
leukocyte reconstitution, including CD4+ and CD8+ T cells that
can respond to activation with the full repertoire of antibacterial
effector molecules. These mice develop productive and dissemi-
nated M.tb infection that causes pathology similar to that observed
in human tissue and several non-rodent animal models. This
represents a significant advance in our ability to study specific
aspects of the human cell-mediated immune response to M.tb.
Moreover, we expect the model to have utility in addressing the
large gaps in our understanding of HIV/M.tb co-infection.
Due to the restricted tropism of HIV to human cells, the various
humanized mouse models have been quickly adopted as the
animal model of choice for HIV research. Studies key to
understanding several important concepts in HIV infection have
been enabled by adoption of this model, including natural routes
of transmission, latency, and effectiveness of vivo antiretroviral
drug prophylaxis [17,18,32,33]. The use of these models has been
expanded to other important infectious agents that previously were
limited by the available animal models, including Dengue virus
[22,34] Plasmodium falciparum [35], Epstein-Barr virus [26], and
Salmonella [21].
Of the various models employed for HIV research, we
considered the BLT mouse developed by J. Victor Garcia-
Martinez and colleagues [26] to be the most appropriate for use in
developing our TB model. Previous reports indicated that human
APC and functional CTL responses could be generated in
response to Epstein-Barr virus infection in this model [26]. This
is important because interactions between macrophages and T
cells (CD4 as well as CD8) are critical in the protective host
response to M.tb. The BLT mice we are now routinely generating
in our collaborative group have a substantial reconstitution of
human leukocytes, similar to previous reports in the BLT and stem
cell reconstituted NSG models [20,26,32]. Also in agreement with
previous studies, we observe circulating and tissue T cells (CD4
and CD8), monocytes/macrophages, DC, and small numbers of
NK cells [18,26].
In the BLT mouse, DC populations have been shown to
constitutively express activation markers that guide the outcome of
DC/T cell interactions [26]. To date, monocyte populations have
only been described in the humanized mouse model where NSG
mice were reconstituted with CD34+ stem cells in the absence of
fetal thymus or liver. In that study, the CD14+ cells were found to
be phenotypically immature and lacked expression of activation
and antigen presentation markers [36]. In our studies in the BLT
mouse model, CD14+ cells from peripheral blood of NSG BLT
mice are shown to constitutively express HLA-DR, CD80, CD86,
Figure 6. Human T cells are recruited to and organize at lung granulomas and sites of inflammation following M.tb infection.
Animals were infected i.n. with 250 colony forming units (CFU) tdTomato H37RV M.tb following establishment of human immune cell populations.
Formalin fixed paraffin embedded tissue sections were cut, dewaxed and stained with antibody to human CD3. Marker expression was visualized
with Fast Red substrate and images captured by brightfield microscopy. A, shown is the localization of T cells relative to a granuloma periphery and
center (top left; 4X, top right; 10X). Enlarged images of T cell staining in the indicated areas are shown in the bottom panels (40X). (B) Human T cells in
portal tracts and sites of inflammation in the liver (top panel, 10X) and an enlarged area showing orchestration of T cells around an inflammatory
focus (bottom panel, 20X). Shown are representative images (n = 3) of animals sacrificed at 7 wk p.i.
doi:10.1371/journal.pone.0063331.g006
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and CD40. Thus, similar to DC populations previously described
[26], the monocyte/macrophage populations in the BLT mice are
phenotypically mature. This is an important observation, as
mononuclear phagocytes, especially macrophages, play critical
roles in several stages of M.tb infection and host response. In
support of macrophage function in humanized mouse models, a
very recent study demonstrated intact phagocytic uptake and IFN-
c-mediated intracellular killing of Salmonella typhi [37].
Cellular immune responses by T cells are required for protective
immunity to M.tb. The importance of secretion of IFN-c by CD4+,
CD8+, and NK cells, is firmly established through studies in gene-
deleted animals and patients with rare genetic defects to be a
necessary effector molecule, activating macrophages to eliminate
the intracellular bacteria [38,39]. In the BLT mouse, we observed
T cell subsets (CD4, CD8) in the blood and various tissues to
express low levels of constitutive as well as activation-induced IFN-
c. Similar to observations of Schultz, et al [27] in a CD34+ stem
cell-reconstituted NSG model, we demonstrate that human CD8
T cells in the BLT mouse constitutively express perforin. Further,
we were able to demonstrate that CD4, CD8 (Fig. 2), and NK cell
(not shown) populations express the antimicrobial granulysin
protein, as well as perforin, upon activation.
Granulysin is an important antibacterial molecule found in
granules of human and cattle cytotoxic T cells and NK cells that is
known to kill intracellular mycobacteria via a perforin-facilitated
mechanism [40–43]. The lack of a granulysin gene homologue in
rodents has limited studies of the role of this antibacterial molecule
in protective immunity. Levels of granulysin in human plasma
have been shown to correlate with successful TB recovery [44] and
selective expression of granulysin in the granuloma periphery in a
cattle model and human autopsy tissue indicate a potentially
important role in the host response to mycobacteria in the lung
[45,46]. The potential to further study expression of granulysin
during M.tb infection in vivo is an exciting aspect of the BLT TB
model. This avenue of investigation is also important for
subsequent HIV/M.tb co-infection studies, as activation of T
and NK granulysin expression has been shown to be very
susceptible to HIV-mediated suppression in patients and an
in vitro model [30,47,48]. In subsequent studies, we will further
evaluate granulysin as a potential biomarker, or part of a
biosignature, that predicts the state of the host response to M.tb.
The use of a fluorescent isolate of M.tb allowed us to follow the
kinetics of infection as has previously been described for traditional
mouse models [31,49]. Similar to these studies, we observed a
progressive increase in bacterial burden over time in the lung
though signal strength declined after 4 weeks presumably due to
loss of the plasmid encoding the red fluorescent protein. Thus this
technique was informative in our studies but requires further
development using an isolate with a gene for fluorescent protein
expression stably integrated into the M.tb genome. Ultimately, the
optimization of this technique for use in our humanized mouse
model allowed us to follow disease progression and make decisions
on necropsy time points. This is especially important in this model
due to the expense and limited number of animals compared to
the use of traditional, non-humanized mice. In subsequent studies,
the use of in-vivo imaging will be an important tool for visualizing
the kinetics of co-infection, or experimental drug or vaccine
treatments effects, using fluorescent or bioluminescent HIV and
M.tb isolates.
The growth of M.tb indicated by our in vivo imaging in the weeks
following infection was confirmed by CFU enumeration of tissue
bacterial burden. The bacterial burden in the spleen and liver
were generally 1 log less than in the lung at the same time point;
an expected pattern of M.tb dissemination based on other animal
models. Regardless of dose, prior to 3–4 weeks of infection, the
disease pathology we observed was similar to that reported in
many mouse models with small but organized foci of inflammation
increasing in prominence. After 4 weeks, however, we observed a
striking difference in lung pathology, with the development of
large granulomatous lesions. Of note, we observed a spectrum of
inflammation within individual lungs by 4 weeks of infection
ranging from small foci of inflammation to large coalescing
granulomas within the same lung lobe. As disease progressed in
our lower dose studies these lesions expanded, coalesced, and
became increasingly caseous and necrotic. The center of the
growing granulomas was accellular, and AFB was primarily found
in the periphery instead of the center of the lesion, consistent with
human TB disease pathology in the lung.
The non-reconstituted NSG mouse did not reproduce the TB
disease that we observed in the BLT mouse. These mice lacking
human immune cell reconstitution developed an inflammatory
disease that was characterized by small but organized foci of
infection in the lung and dissemination to the spleen and liver.
Surprisingly, 2 of the 4 infected animals survived to 5–6 weeks
and, based on tissue pathology and bacterial load, may have
survived much longer than these planned time points. By 6 weeks
p.i., however, the NSG mice failed to develop the large, organized,
granulomas that were observed in the BLT mice by 4 wk p.i.
Though this demonstrates the contribution of the human cells for
development of important features of TB pathology in the model,
it is still very interesting that these severely immune-compromised
animals survived several weeks post infection. Traditional mouse
models with targeted deletions of important immune mechanisms,
such as the IFN-c deficient (GKO) mice that are highly susceptible
to M.tb, succumb to the infection within 5–8 weeks after a low dose
inoculum of 50–200 CFU [39,50]. The Kramnik (C3HeB/FeJ)
mouse model, which is also highly susceptible to M.tb, succumb to
the disease within 4–12 weeks depending on dose [10,51]. Like
these models, the NSG mouse retains functional murine neutro-
phils which have an increasingly appreciated role in controlling
infection with intracellular bacteria.
A critical observation in our studies was the granuloma lesion
with central necrosis; considered the hallmark of human tubercu-
losis infection [10,50,52]. Non-human primates and guinea pigs do
form the classic granulomatous lung response and are thus
considered excellent models to study TB pathogenesis. Widely
used mouse models of M.tb infection, such as the BALB/c and
C57BL/6, do not show necrotic granuloma lesions or a spectrum
of lesions that is associated with human disease [10,50,52].
Necrotic granuloma lesions have been observed in immunosup-
pressed mouse models including the GKO and C3HeB/FeJ model
[10,39,51,52] or mice treated with Trehalose 6,69-dimycolate [53],
an M.tb cell wall glycolipid that initiates a CD3+T cell-mediated
inflammatory response [54].
Another interesting feature of our model is the cholesterol
crystal formation in the lung lesions that we observed. Cholesterol
catabolism is important for M.tb growth and genes specific to
cholesterol and general lipid metabolism have been identified as
part of the differential M.tb transcriptome specific to intracellular
growth in macrophages [55]. We additionally observed frequent
bronchial obstructions that were dense in AFB, a characteristic
feature of human lung TB that, to our knowledge, has not been
previously observed in mouse models. Bronchiole obstruction in
afflicted humans is believed to be important in disease transmis-
sion due to expulsion of AFB upon coughing [11,56]. Endobron-
chial M.tb is thought to be an indicator of bacterial spread in the
lungs and an early indicator of post-primary TB [57]. Though
mice lack the cough reflex, the development of the obstruction is
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an important endpoint in the model and will allow investigation of
this hallmark of human disease in the animal model. In contrast to
the GP and NHP models, we did not observe fibrosis or
calcification in any animals infected with M.tb. However, in these
initial studies we did not allow infection to progress beyond 6
weeks in most experiments, with the maximum time point of 8
weeks. Future studies with an extended time frame and aerosol-
delivery of infection will be performed to study survival and
pathology at later stages of infection.
Importantly, in our studies, human T cells were found at the
granuloma periphery; a controversial feature of disease with
regards to bacterial containment, on-going antigen presentation,
and immune-mediated pathology [58]. The recruitment of T cells
to these sites of infection will enables several avenues of
investigation important for vaccine design, including studies of
human memory T cell populations and effector molecule profiles
associated with specific pathology. It will additionally allow us to
evaluate the impact of HIV infection on T cell mediated immunity
in the lungs. Upon further optimization of infection, it may
additionally be possible to develop a latency model, similar to the
Cornell model [59], in the BLT mouse.
In summary, our studies support further exploration of the
humanized BLT mouse for basic and translational TB research.
The expense of generating BLT mice is a limitation compared to
traditional mouse, guinea pig, and rabbit models; although,
compared to the expense of the NHP, BLT mice are considerably
cheaper. Additionally, the availability of human reagents including
antibodies, multi-plex protein arrays, and HLA-matched tetra-
mers/pentamers is a significant advantage to the model. An
important application of this model specific to our laboratory’s
interests will be the further development of an HIV/M.tb co-
infection model. Further development of this co-infection model
could generate a powerful research tool for use to understand the
pathobiology of co-infection and to test medical countermeasures.
Materials and Methods
Ethics Statement
All animal procedures were performed in accordance with the
regulations of the NIH Office of Laboratory Animal Welfare and
were approved by the University of Texas Medical Branch
(UTMB) Institutional Animal Care and Use Committee (IACUC).
Discarded tissue from deceased human fetuses was obtained via a
non-profit partner (Advanced Bioscience Resources, Alameda,
CA) as approved under exemption 4 in the HHS regulations (45
CFR Part 46).
Generation of Humanized BLT Mice
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice, also known as NOD/
SCID/cc
null or NSG mice (Jackson Laboratories), 3–5 weeks of
age, were housed in a specific pathogen-free microisolator
environment. Mice were engrafted with human fetal liver and
thymus (Advanced Bioscience Resources, Alameda, CA) tissue
after receiving 200 cGy of irradiation at a rate of 119 cGy/min
(RS-200 Rad Source, Suwanee, GA) as previously described [26].
Following engraftment of tissue, mice were intravenously (i.v)
injected with approximately 16106 hematopoietic stem cells
(CD34+ cells) per mouse from the same human fetal tissue donor.
For two weeks after implantation, mice received acidified drinking
water (pH 3.0) with antibiotics. Twelve weeks post-engraftment,
human leukocyte reconstitution was evaluated in peripheral blood.
Animal Infections
M.tb (tdTomato H37Rv) was propagated by growth to log phase
in Middlebrook 7H9 broth (Becton, Dickinson, and Company,
Sparks, MD, USA) supplemented with 50% glycerol (Sigma, St.
Louis, MO, USA), BBL Middlebrook albumin dextrose complex
enrichment (ADC, BD), and 20% Tween 80 (Fisher Scientific, Fair
Lawn, NJ, USA) as previously described [60]. Mice were infected
intranasally with 40 ml (20 ml/nare) of logarithmically decreasing
doses (106–102 CFU) of M.tb tdTomato H37Rv diluted in
Dulbecco’s Phosphate-Buffered Saline (PBS, Cellgro, Manassas,
VA, USA). The actual dose was further confirmed by CFU
enumeration of inoculum suspension. At specified time points,
mice were euthanasized using isoflurane (Primal Critical Care,
Inc., Bethlehem, PA) overdose. Cervical dislocation was subse-
quently performed to ensure death, as approved by the UTMB-
IACUC. All animal experiments and work with M.tb were
performed in a CDC-approved animal biological safety level-3
(ABSL-3) and BSL3 facilities in the Galveston National Labora-
tory in accordance with biosafety procedures approved by the
UTMB Environmental Health and Safety Division.
In-vivo Imaging
Mice were anesthetized with 3% isoflurane (Piramal Critical
Care, Inc. Bethlehem, PA, USA) in an oxygen-filled induction
chamber, transferred to an isolation chamber, and placed in the
imaging chamber which contains an integrated anesthesia system.
Anesthesia was continued to be administered at 1–2% isoflurane.
In-vivo fluorescent images were acquired using the In-Vivo Imaging
System (IVIS) Spectrum (Caliper Corporation, Alameda, CA,
USA). Images were acquired at each excitation and wavelength
pair as previously described [61]. The fluorescent signal was
obtained at a 535 nm and 605 nm excitation light and read at
580, 620, 640, 660, 680, 700 nm. Compensation was applied to
correct for autofluorescence.
Isolation of PBMCs and Leukocyte Analysis
Reconstitution levels of lymphocytes and monocytes were
determined pre- and post-infection by multi-variate flow cytom-
etry. Peripheral blood was collected from the tail vein of
humanized BLT mice and placed in 500 ml 3 mM ethylenedi-
aminetetraacetic acid (EDTA, Capitol Scientific, Austin, TX,
USA). Peripheral blood mononuclear cells (PBMCs) were isolated
by incubation with Red Blood Cell Lysis Buffer (Sigma, St. Louis,
MO, USA) as recommended by manufacturer. Subsequently,
PBMC were incubated with CD16/CD32 Fc Block (BD
Biosciences, San Jose, CA, USA) to reduce non-specific binding
of antibodies. Cells were labeled with directly conjugated
antibodies specific to human lymphocyte surface markers: PE-
Cy7 CD45, Alexa Fluor 700 CD56, APC Cy7 CD3, Pacific Blue
CD4, and PerCP-Cy5.5 CD8 (BD Biosciences) and is a separate
experiment, cdTCR (eBioscience). In some experiments PBMC
were labeled with antibody to human antigen presenting cell
phenotype and activation markers: APC-Cy7 CD14, PE-Cy7
CD40, PerCP-Cy5.5 HLA-DR, FITC CD80, and PE CD86
cdTCR (BD Bioscience). For determination of effector function,
spleens from non-infected humanized mice were obtained and
processed to single-cell suspensions by pressing through a 70 m
filter. Following incubation with Red Blood Cell Lysis Buffer,
PBMCs were maintained in complete culture medium (cRPMI),
RPMI 1640 supplemented with 10% fetal bovine serum (FSB),
2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM nonessential
amino acids, and 1% penicillin-streptomycin (Life Technologies,
Grand Island, NY, USA) and stimulated with IL-15 (15 ng/ml) or
CD3/28, a T-cell stimulant, for 5 days (as recommended by the
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manufacturer Life Technologies),. Cells were treated with Golgi-
Stop (BD Bioscience) during the last 5 hours of culture, washed,
and subsequently labeled using antibodies to human lymphocyte
surface markers. Cells were permeabilized using the BD Cytofix/
Cytoperm kit (BD Bioscience), then labeled with antibodies
specific to human APC IFN-c, FITC granulysin, PE-Perforin, or
PE Ki-67, a proliferation marker (BD Bioscience). Samples were
finally incubated for 48 hours in 2% formaldehyde (Polysciences
Inc, Warrington, PA, USA) diluted in PBS prior to acquisition. A
total of 50,000 gated events (based on expected leukocyte side
scatter/forward scatter characteristics) were collected using a BD
LSR II (Fortessa) flow cytometer (BD Biosciences). Analysis of data
was performed by FCS Express (De Novo, Los Angeles, CA, USA)
software. To control for background and to establish thresholds for
gating positive cells, isotype matched antibodies labeled with the
same fluorochromes were used. Cells were selected based on the
human CD45 marker and further analyzed for human CD3, CD4,
CD8, CD56, and CD14.
CFU Enumeration
At specified time points, following aseptic removal of organs,
half of the liver, lungs, and spleen were placed into 1 ml of PBS in
50 ml small tissue grinders (Kendall, Mansfield, MA, USA).
Following homogenization of tissues, serial dilutions of organ
samples were prepared in PBS, and 6–5 ml droplets were placed on
7H11 agar plates (BD Biosciences) as previously described [42]. All
studies were performed in a CDC-approved biological safety level-
3 (BSL-3) facility.
Pathology Assessment
At specified time points, following aseptic removal of organs, the
remaining half of tissues were placed in 10% Neutral Buffered
Formalin (Statlab, McKinney, TX, USA) for 48 hours to
inactivate infectious agent, changed after 24 hours, and finally
stored in 70% ethanol. Tissues were embedded in paraffin then
stained with hematoxylin and eosin (H&E) and additional sections
were stained using the Ziehl-Neelson method to visualize acid-fact
bacteria (AFB) to detect M.tb bacilli. Processing and staining were
performed at the University of Texas Medical Branch Research
Histopathology Core. Paraffin embedded tissue samples were
further stained using EnVisionTM G|2 System/AP, Rabbit/
Mouse (Permanent Red) (Dako, Carpinteria, CA) for human
CD3 (Dako) according to manufacture recommendations. Lung,
liver, and spleen tissue was evaluated by a trained pathologist with
expertise in tuberculosis disease progression, with confirmation
done in a slide blinded manner by pathologists at the UT-Houston
Medical School.
Supporting Information
Figure S1 Tissue distribution of leukocytes in human-
ized BLT mice. Tissues (lung, spleen and liver) from non-
infected animals were disrupted to single-cell suspensions and
analyzed by flow cytometry. Total human leukocytes were gated
based on CD45 expression and further analyzed for phenotype
using antibodies specific to human CD4, CD8, CD56, and CD14.
Shown is the percentage of the total cells that express human
CD45, and the % of the gated cells that express markers that
identify T cell subsets (CD4, CD8), NK cells (CD56), and
monocyte/macrophages (CD14). Data are from a representative
BLT mouse within the groups described in Figure 1.
(TIF)
Figure S2 M.tb infection in non-reconstituted NSG mice
differs from that observed in humanized mice. NSG mice
that were not engrafted with human tissue or stem cells were
infected i.n. with M.tb. Shown are images captured by brightfield
microscopy following staining of infected tissues using H&E and
acid fast stain. Shown in A are lung, and B, liver, tissue pathology
and localization of AFB at 2 and 6 weeks p.i. (H&E 4X, AFB 40X).
Results are representative of mice sacrificed at 2 and 6 wk p.i.
(TIF)
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